Do autoantibodies shape cancer immunosurveillance?
Bastard P., Hulett T., Smith-Byrne K., Landegren N., Mogensen TH., Fellay J., Travis RC., Casanova J-L., Dang CV., Lu X.
Why cancer arises, progresses, or proves fatal in some people but not others remains largely unresolved. Antibody repertoires, including autoantibodies targeting immune pathways, may shape cancer immunosurveillance. Mapping antibody landscapes across cancer-free, at-risk, and cancer-affected individuals could clarify their roles in cancer susceptibility and disease outcome.